<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="6571">
  <stage>Registered</stage>
  <submitdate>7/02/2017</submitdate>
  <approvaldate>7/02/2017</approvaldate>
  <nctid>NCT03048604</nctid>
  <trial_identification>
    <studytitle>BiLAteral Hypoglossal Nerve Stimulation for Treatment of Obstructive Sleep Apnoea (BLAST OSA)</studytitle>
    <scientifictitle>A Multicentre, Prospective, Open-label, Non-randomized, Single Arm Treatment Study to Assess the Safety, Performance and Initial Efficacy Trends of the Genio(TM) Bilateral Hypoglossal Nerve Stimulation System for the Treatment of Obstructive Sleep Apnoea.</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>BLAST OSA</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Obstructive Sleep Apnea of Adult</healthcondition>
    <conditioncode>
      <conditioncode1>Respiratory</conditioncode1>
      <conditioncode2>Sleep apnoea</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: devices - Genio(TM) bilateral hypoglossal nerve stimulation system

Experimental: Genio(TM) system therapy - 


Treatment: devices: Genio(TM) bilateral hypoglossal nerve stimulation system
Subjects will be consented, enrolled and eligibility criteria checked. If the subject is eligible, subject will proceed with the Genio(TM) implant implantation. Four (4) weeks after implantation, the implant will be activated and the subject will be assessed at 1 month plus 1 week, 2, 3, 4 and 6 month(s) after implantation.

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: devices</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Safety (Incidence of serious device-related adverse events) - Incidence of serious device-related adverse events</outcome>
      <timepoint>6-months post implantation</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Performance - Change from baseline to 6-month post implantation in the apnoea-hypopnea index (AHI)</outcome>
      <timepoint>6-months post implantation</timepoint>
    </primaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Main 

          -  Body mass index =32 kg/m2

          -  Patients who do not tolerate or do not accept positive airway pressure (PAP)
             treatments.

          -  Obstructive apnoea-hypopnea index (AHI) of 20-60 events/hour

        Main</inclusivecriteria>
    <inclusiveminage>21</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>75</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  Unable or incapable of providing informed written consent

          -  Unwilling or incapable of returning to all follow-up visits and sleep studies,
             including evaluation procedures and filling out questionnaires

          -  Significant co-morbidities making the patient unable or inappropriate to participate
             in the trial</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation />
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Single group</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Not Applicable</phase>
    <anticipatedstartdate />
    <actualstartdate>30/03/2017</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize>25</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Recruiting</recruitmentstatus>
    <anticipatedlastvisitdate>1/03/2018</anticipatedlastvisitdate>
    <actuallastvisitdate />
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>Pert</recruitmentstate>
    <hospital>Hollywood Private UWA Centre for Sleep Science Facility - Nedlands</hospital>
    <postcode> - Nedlands</postcode>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Paris</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>London</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Nyxoah S.A.</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>The study is designed as a prospective, open-label, multicentre, non-randomized, single arm
      treatment study to assess the safety, performance and initial efficacy trends of the GenioTM
      System in patients with Obstructive Sleep Apnoea (OSA).</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT03048604</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Valérie Attali, Dr.</name>
      <address>La Pitié Salpêtrière, Paris</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name>Nathalie Gilat</name>
      <address />
      <phone />
      <fax />
      <email>clinical@nyxoah.com</email>
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>